trial

A Study to Examine the Pharmacodynamic Effects of GSK1034702 on Neurophysiological Biomarkers of Cognition in Nicotine Abstained Otherwise Healthy Smokers

NCTId NCT01371799
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 9 (actual)
Sponsored by GlaxoSmithKline
Primary completion 2010-06-18
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
9 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2009-12-17
Primary completion
2010-06-18
Eligibility
MALE · 18 Years · 55 Years

Interventions & indications

Drugs
Drug

Sponsors

GlaxoSmithKlineLead Sponsor

Sites

1 total
Cambridge, United Kingdom

Facts & assertions

4 sourced
Enrollment
9
Phase
PHASE1
Primary Completion Date
2010-06-18
Status
COMPLETED
relationships
The graph out of here
drug
Drug
drug
lead_sponsor
GlaxoSmithKline
company
indication
Schizophrenia
indication
Mental Disorders
indication
Mental Disorders
indication